News

Categories

December 8, 2023

Updated Phase 2a Data Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer Presented at SABCS 2023

November 30, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

November 7, 2023

Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results

November 4, 2023

Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference

November 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

October 20, 2023

Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress

October 17, 2023

Zymeworks To Host Third Quarter 2023 Results Conference Call

October 16, 2023

Zymeworks Announces New Director Nominee

October 16, 2023

Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023

September 27, 2023

Zymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences

August 10, 2023

Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences